我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Adrenalectomy for Bilateral Metachronous Adrenal Recurrence of Hepatocellular Carcinoma after Liver Transplant

David L Morris

Hepatocellular melanoma is the fifth most common cancer in the world and the third leading cause of cancerrelated death. It's presently one of the leading suggestions for liver transplant, with named 5- time survival rates after liver transplant of about 70. Despite excellent results of liver transplant for hepatocellular melanoma, a number of cases develop metastases after transplant, and multifocal metastatic complaint is the most frequent cause of death. In a large necropsy series of cases with hepatocellular melanoma, adrenal glands were the third most common point of extra hepatic metastasis after lungs and bones. Still, insulated metastatic complaint in the adrenal glands is rare, and insulated Metachronous bilateral metastasis is an indeed rarer circumstance. Only many reports have been published of Metachronous bilateral metastasis of hepatocellular carcinoma after liver transplant treated with bilateral Adrenalectomy. We describe a case of a 56- time-old man who passed liver transplant for hepatocellular melanoma in a cirrhotic liver. Two times after liver transplant, regular follow- up revealed metastatic complaint in the left adrenal gland. Preoperative imaging showed no other metastasis, and he passed an uneventful left Adrenalectomy. A time after surgery, he presented with right hand pain and tender-heartedness. Imaging showed haemorrhage and excrescence involvement of the right adrenal gland, and he passed right Adrenalectomy. Two times after surgery, he's alive and well with no signs of complaint rush. Supposedly, in the absence of intrahepatic or other metastases, bilateral Metachronous rush of hepatocellular melanoma after liver transplant can be a good surgical suggestion with respectable long- term survival [1-2].

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。